BioAge Labs is a biotechnology company focused on leveraging artificial intelligence and machine learning to unlock the biology of aging and develop therapeutics that can extend healthy lifespan. The company harnesses its proprietary platform to analyze vast amounts of biological data in order to identify and validate novel drug targets linked to aging-related diseases. Through its innovative research, BioAge aims to create effective therapies that not only treat age-associated conditions but also improve overall health and longevity in individuals. Read More
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioAge Labs, Inc. (NASDAQ: BIOA) on behalf of long-term stockholders following a class action complaint that was filed against BioAge on January 7, 2024 with a Class Period pursuant and/or traceable to BioAge’s registration statement for the initial public offering held on or about September 26, 2024. Our investigation concerns whether the board of directors of BioAge have breached their fiduciary duties to the company.
Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy
Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for aging-related diseases
EMERYVILLE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioAge Labs, Inc. (NASDAQ: BIOA) on behalf of long-term stockholders following a class action complaint that was filed against BioAge on January 7, 2024 with a Class Period pursuant and/or traceable to BioAge’s registration statement for the initial public offering held on or about September 26, 2024. Our investigation concerns whether the board of directors of BioAge have breached their fiduciary duties to the company.
RICHMOND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided business updates and reported its first quarter 2025 financial results.
